Literature DB >> 15994222

Diagnosis and treatment of Alzheimer's disease.

Abhilash K Desai1, George T Grossberg.   

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia. It is one of the principal causes of disability and decreased quality of life among older adults. Progress in our clinical knowledge of AD has led to more reliable diagnostic criteria and accuracy, and research efforts are expanding to uncover the earliest manifestations and even the presymptomatic phases of the disease. The diagnosis of AD is primarily one of inclusion and usually can be made using standardized clinical criteria. There is currently no cure for AD. Current treatment focuses on establishing an early accurate clinical diagnosis, early institution of cholinesterase inhibitors and/or N-methyl-D-aspartate (NMDA) receptor-targeted therapy. Treating medical comorbidities and dementia-related complications, ensuring that appropriate services are provided, addressing the long-term well-being of caregivers, and treating behavioral and psychological symptoms with appropriate nonpharmacologic and pharmacologic interventions also are important. The initiating and propagating pathologic processes and the anatomic location of the earliest changes will become new targets of research and therapeutic development. A possible precursor of AD, mild cognitive impairment (MCI), is under investigation as a possible therapeutic starting point for disease-modifying interventions. This article provides a research update of current understanding in the diagnosis and treatment of AD and in emerging areas of interest such as MCI, detection of AD in the predementia phase, and neuroimaging in AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994222     DOI: 10.1212/wnl.64.12_suppl_3.s34

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's Disease.

Authors:  Lubov E Zeifman; William F Eddy; Oscar L Lopez; Lewis H Kuller; Cyrus Raji; Paul M Thompson; James T Becker
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Learning in Alzheimer's disease is facilitated by social interaction.

Authors:  Melissa C Duff; Diana R Gallegos; Neal J Cohen; Daniel Tranel
Journal:  J Comp Neurol       Date:  2013-12-15       Impact factor: 3.215

3.  Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice.

Authors:  Andréia M Pazini; Guilherme M Gomes; Jardel G Villarinho; Claudio da Cunha; Francielle Pinheiro; Ana P O Ferreira; Carlos F Mello; Juliano Ferreira; Maribel A Rubin
Journal:  Neurochem Res       Date:  2013-09-05       Impact factor: 3.996

4.  Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients.

Authors:  Christoph Zenzmaier; Josef Marksteiner; Andreas Kiefer; Peter Berger; Christian Humpel
Journal:  J Neurochem       Date:  2009-05-11       Impact factor: 5.372

5.  Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage.

Authors:  Thomas Kukar; Todd E Golde
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

6.  Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer's disease.

Authors:  Josef Marksteiner; Christian Humpel
Journal:  Curr Neurovasc Res       Date:  2013-11       Impact factor: 1.990

7.  Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study.

Authors:  Josef Marksteiner; Douglas Imarhiagbe; Michaela Defrancesco; Eberhard A Deisenhammer; Georg Kemmler; Christian Humpel
Journal:  Exp Gerontol       Date:  2013-12-10       Impact factor: 4.032

8.  Novel information on the non-neuronal cholinergic system in orthopedics provides new possible treatment strategies for inflammatory and degenerative diseases.

Authors:  Sture Forsgren; Håkan Alfredson; Dennis Bjur; Solbritt Rantapää-Dahlqvist; Orjan Norrgård; Tore Dalén; Patrik Danielson
Journal:  Orthop Rev (Pavia)       Date:  2009-06-30

Review 9.  Identifying and validating biomarkers for Alzheimer's disease.

Authors:  Christian Humpel
Journal:  Trends Biotechnol       Date:  2010-10-23       Impact factor: 19.536

Review 10.  Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications.

Authors:  Luiz Kobuti Ferreira; Geraldo F Busatto
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.